Cytokine induced killer cells as promising immunotherapy for solid tumors

Journal of Cancer

Volumn 2, Issue 1, 2011, Pages 363-368

  Sangiolo, Dario ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

Adoptive immunotherapy; CIK cells; Solid tumors

Indexed keywords

CYTOKINE; NATURAL KILLER CELL RECEPTOR NKG2D;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; DONOR LYMPHOCYTE INFUSION; EX VIVO STUDY; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HLA SYSTEM; HUMAN; IMMUNOTHERAPY; KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MINIMUM INHIBITORY CONCENTRATION; MONONUCLEAR CELL; NONHUMAN; PHENOTYPE; RISK ASSESSMENT; SOLID TUMOR; T LYMPHOCYTE; TUMOR CELL;

EID: 84855520803     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2.363     Document Type: Article

References (50)

1. Schmidt-Wolf I.G, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol, 1993. 21(13): 1673-9.
2. Schmidt-Wolf I.G, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J.Exp.Med, 1991. 174(1): 139-149.
3. Lu P.H and Negrin R.S. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J. Immunol, 1994. 153(4): 1687-1696.
4. Introna M, et al. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant, 2006. 38(9): 621-627.
5. Hayes M.P, Wang J, and Norcross M.A. Regulation of interleu-kin-12 expression in human monocytes: selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes. Blood, 1995. 86(2): 646-50.
6. Ma X, et al. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J Exp Med, 1996. 183(1): 147-57.
7. Lopez R.D, et al. CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells. Cancer Immunol Immunother, 2001. 49(12): 629-40.
8. Ochoa A.C, et al. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta. Immunol J, 1987. 138(8): 2728-33.
9. Anderson P.M, Bach F.H, and Ochoa A.C. Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma. Cancer Immunol Immunother, 1988. 27(1): 82-8.
10. Zoll B, et al. Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12. Cancer Immunol Immunother, 1998. 47(4): 221-6.
11. Leemhuis T, et al. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant, 2005. 11(3): 181-7.
12. Baker J, et al. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood, 2001. 97(10): 2923-31.
13. Sangiolo D, et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol, 2008. 20(7): 841-8.
14. Bonanno G, et al. Thymoglobulin, interferon-gamma and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures. J Transl Med, 2010. 8: 129.
15. Li H, et al. CD4 +CD25 + regulatory T cells decreased the anti-tumor activity of cytokine-induced killer (CIK) cells of lung cancer patients. J Clin Immunol, 2007. 27(3): 317-26.
16. Todorovic M, Gammaitoni L, Leuci V, et al. Ex-vivo Allogeneic Stimulation Significantly Improves Expansion of Cyto-kine-Induced Killer Cells without Increasing their Alloreactiv-ity across MHC-barriers. EHA. 2011; epub.
17. Linn Y.C, et al. Characterization of the recognition and func-tional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell. Immunology, 2009 Mar;126(3):423-35.
18. Verneris M.R, et al. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol. Blood Marrow Transplant, 2001. 7(10): 532-542.
19. Yang Y.G, et al. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. J Clin Invest, 1998. 102(12): 2126-35.
20. Nishimura R, et al. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood, 2008. 112(6): 2563-74.
21. Introna M, et al. Repeated infusions of donor-derived cyto-kine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica, 2007. 92(7): 952-959.
22. Verneris M.R, et al. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood, 2004. 103(8): 3065-3072.
23. Jamieson A.M, et al. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity, 2002. 17(1): 19-29.
24. Diefenbach A, et al. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of cells NK and macrophages. Nat Immunol, 2000. 1(2): 119-26.
25. Cosman D, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity, 2001. 14(2): 123-33.
26. Groh V, et al. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A, 1999. 96(12): 6879-84.
27. Sangiolo D, et al. MIC A/B Protein Expression Associates with Trastuzumab-Resistant Breast Cancer Cells Leading to Effective Immunotherapy by Cytokine Induced Killer Cells. ASH. 2009; epub.
28. Schmidt-Wolf I.G, et al. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol, 1996. 169(1): 85-90.
29. Sangiolo D, et al. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. Expert Opin Biol Ther, 2009. 9(7): 831-40.
30. Kuci S, et al. Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immuno-therapy after allogeneic stem cell transplantation. Haematologica, 2010. 95(9): 1579-86.
31. Hongeng S, et al. Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells. Int Hematol J, 2003. 77(2): 175-9.
32. Wongkajornsilp A, et al. Human cytokine-induced killer cells specifically infiltrated and retarded the growth of the inocu-lated human cholangiocarcinoma cells in SCID mice. Cancer Invest, 2009. 27(2): 140-8.
33. Chan J.K, et al. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin. Cancer Res, 2006. 12(6): 1859-1867.
34. Kim H.M, et al. Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model. Arch Pharm Res, 2009. 32(5): 781-7.
35. Schmidt-Wolf I.G, et al. Propagation of large numbers of T cells with natural killer cell markers. Br.J.Haematol, 1994. 87(3): 453-458.
36. Sangiolo D, et al. Effective preclinical adoptive immunotherapy with cytokine-induced killer cells for bone sarcomas. EBMT. 2011; epub.
37. Verneris M.R, et al. Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Clin Cancer Res, 2005. 11(12): 4561-70.
38. Schmidt-Wolf I.G, et al. Phase I clinical study applying autologous immunological effector cells transfected with the inter-leukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br Cancer J, 1999. 81(6): 1009-16.
39. Tita-Nwa F, et al. Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells. Cancer Immunol Immunother, 2007. 56(12): 1911-20.
40. Marin V, et al. Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal. Exp Hematol, 2007. 35(9): 1388-97.
41. Yoon S.H, et al. Transfer of Her-2/neu specificity into cyto-kine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR). J Clin Immunol, 2009. 29(6): 806-14.
42. Olioso P, et al. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol, 2009; epub.
43. Hui D, et al. A randomized controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis, 2009. 41(1): 36-41.
44. Weng D.S, et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term re-currence rates of hepatocellular carcinomas. Immunother J, 2008. 31(1): 63-71.
45. Shi M, et al. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World Gastroenterol J, 2004. 10(8): 1146-51.
46. Wu C, et al. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res, 2008. 28(6B): 3997-4002.
47. Jiang J, et al. Treatment of advanced gastric cancer by chemo-therapy combined with autologous cytokine-induced killer cells. Anticancer Res, 2006. 26(3B): 2237-2242.
48. Jiang J.T, et al. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World Gastroenterol J, 2010. 16(48): 6155-62.
49. Niu Q, et al. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int Immunopharmacol, 2011. 11(4): 449-56.
50. Hontscha C, et al. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol, 2011. 137(2): 305-10.